Emergence of Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308

Antimicrob Agents Chemother. 2019 Dec 20;64(1):e02112-19. doi: 10.1128/AAC.02112-19. Print 2019 Dec 20.

Authors

Pablo A Fraile-Ribot¹, Cristóbal Del Rosario-Quintana², Carla López-Causapé¹, María A Gomis-Font¹, Mar Ojeda-Vargas², Antonio Oliver³

Affiliations

¹ Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, Palma de Mallorca, Spain.
² Servicio de Microbiología, Hospital Universitario Insular de Gran Canaria, Gran Canaria, Spain.
³ Servicio de Microbiología, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears, Palma de Mallorca, Spain antonio.oliver@ssib.es.

No abstract available

Keywords: AmpC; FOX-4; Pseudomonas aeruginosa; ceftazidime-avibactam; ceftolozane-tazobactam.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Azabicyclo Compounds / pharmacology
Ceftazidime / pharmacology
Drug Combinations
Microbial Sensitivity Tests
Pseudomonas aeruginosa / drug effects*
beta-Lactamase Inhibitors / pharmacology*

Substances

Anti-Bacterial Agents
Azabicyclo Compounds
Drug Combinations
avibactam, ceftazidime drug combination
beta-Lactamase Inhibitors
Ceftazidime